Neurofilaments for NEDA assessing in MS

• Research type

  Research Study

• Full title

  Neurofilament Heavy and Light chain testing for NEDA (No Evidence of Disease Activity) assessing in Multiple Sclerosis: a longitudinal biomarker study

• IRAS ID

  221338

• Contact name

  Sharmilee Gnanapavan

• Contact email

  s.gnanapavan@qmul.ac.uk

• Sponsor organisation

  Barts Health NHS Trust

• Duration of Study in the UK

  3 years, 0 months, 1 days

• Research summary

  Relapsing-remitting multiple sclerosis patients starting or switching to Alemtuzumab treatment will be invited to participate in this two year CSF, blood, urine and stool biomarker study. The biomarkers will be analysed at the end of the study using either in house immunoassays (neurofilaments) or established commercial assays for the other biomarkers. The biomarker profiles will be correlated with imaging and clinical scales to assess their predictive ability in profiling the underlying disease pathophysiology. The ultimate goal is to envisage whether neurofilaments or a group of biomarkers can be used to indicate disease activity or lack thereof, following treatment.

• REC name

  South Central - Berkshire B Research Ethics Committee

• REC reference

  17/SC/0212

• Date of REC Opinion

  22 May 2017

• REC opinion

  Further Information Favourable Opinion